Is MGNX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MGNX. It does not provide personalized investment advice.

MGNX (MacroGenics, Inc.) Stock Analysis - Financials

MacroGenics, Inc. (MGNX) is a publicly traded Healthcare sector company. As of September 9, 2026, MGNX trades at $4.00 with a market cap of $275.18M and a P/E ratio of -3.48. MGNX moved -4.86% today. Year to date, MGNX is +155.28%; over the trailing twelve months it is +137.57%. Its 52-week range spans $0.99 to $5.08. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces MGNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are MGNX's key financials?

MGNX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. MGNX recently traded at $4.00. Market cap is $275.18M. P/E ratio is -3.48. Revenue is $149.50M.

MGNX Key Metrics

Key financial metrics for MGNX
Metric	Value
Price	$4.00
Market Cap	$275.18M
P/E Ratio	-3.48
EPS	$-1.18
Dividend Yield	0.00%
52-Week High	$5.08
52-Week Low	$0.99
Volume	511.40K
Avg Volume	0
Revenue (TTM)	$149.50M
Net Income	$-74.62M
Gross Margin	0.00%

MGNX Analyst Consensus

4 analysts cover MGNX: 0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.

Common questions about MGNX

What are MGNX's key financials?: MGNX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. MGNX recently traded at $4.00. Market cap is $275.18M. P/E ratio is -3.48. Revenue is $149.50M.
Is MGNX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MGNX. It does not provide personalized investment advice.